Meeting
2017 ASCO Annual Meeting
Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.
Authors
Daniele Rossini
Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
Daniele Rossini , Roberto Moretto , Chiara Cremolini , Vittorina Zagonel , Giuseppe Tonini , Vincenzo Ricci , Giuseppe Aprile , Sara Lonardi , Gianluca Tomasello , Emanuela Dell'Aquila , Giacomo Allegrini , Francesca Bergamo , Marialaura Mancini , Carlotta Antoniotti , Monica Ronzoni , Alberto Zaniboni , Federica Marmorino , Sara Bustreo , Elena Mori , Alfredo Falcone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3542)
DOI
10.1200/JCO.2017.35.15_suppl.3542
Abstract #
3542
Poster Bd #
165
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).
First Author: Karam Ashouri
Poster
2023 ASCO Annual Meeting
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
First Author: Kentaro Yamazaki
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz